Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Shares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader...» Read More
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.
CNBC's Jim Cramer and David Faber discuss Express Scripts' selection of AbbVie over Gilead for its hepatitis C drug and what this means for Gilead.
"We're trying to develop treatments that offer new hope or patients battling cancer," says Hans Bishop, Juno Therapeutics CEO, explaining the technology behind Juno.
Because of its anti-coagulant drug, FXI, Mad Money's Jim Cramer thinks Isis Pharmaceuticals can climb much higher.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.
Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.
Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.
CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.
Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.
A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.
CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.
Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."
Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.
CNBC's Bertha Coombs takes a close look at the wild swings taking place in the biotech sector.
Matthew Roden, executive director of biotechnology equity research at UBS argued biotech stock valuations are still attractively valued even after their run higher.
Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.
The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."
CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.